AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01629173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic impression insole
Description: We sequentially padded (1)a 6.5-mm thick P-cell (21 Shore A hardness, Acor orthopedic Inc. Cleveland, Ohio, USA), and (2)a piece of metatarsal pad and arch support made of Ethylene Vinyl Acetate (EVA) (40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) to the bottom of the impressed 9-mm thick plastazote (15 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) with double-sided adhesive tape in the forefoot region and just proximal to the first, second, and third metatarsal head region. We additionally padded a 2-mm thick Multiform (30 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) on the top of the impressed insole with double-sided adhesive tape.
Study NCT01629173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Custom molded insole
Description: The custom molded insole was made by sequentially padded Multiform (30 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany), P-cell (21 Shore A hardness, Acor orthopedic Inc. Cleveland, Ohio, USA), Ethylene Vinyl Acetate (EVA)(40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany), and cork (50 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) on the positive plaster cast impressed by an impression box while holding the subtalar joint at a neutral position.
Study NCT01629173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 9-mm uncompressed Plastazote
Description: We used 9-mm flat Plastazote(15 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) as an insole
Study NCT01629173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 7-mm Ethylene Vinyl Acetate (EVA)
Description: We used 7-mm flat Ethylene Vinyl Acetate (EVA) (40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) as an insole
Study NCT01651871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-555739 Dose 1
Study NCT01651871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-555739 Dose 2
Study NCT01651871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine HCl Dose 1
Study NCT01651871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine HCl Dose 1
Study NCT01651871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-555739 placebo
Study NCT01651871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-555739 placebo
Study NCT01651871 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S-555739 placebo
Study NCT01651871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine HCl placebo
Study NCT01651871 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cetirizine HCl placebo
Study NCT01415401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1% / timolol 0.5% maleate fixed combination
Study NCT04468841 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cfDNA testing
Description: peripheral blood samples collected before initiation of standard therapy, after 2 cycles of therapy, at the completion of 6-8 cycles of induction therapy, and then every 6 months for a total of 2 years from the initiation of therapy using a cfDNA assay. For retrospective patients, blood samples will be collected once.
Study NCT03666494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: As part of the patient's anesthetic induction, they will receive fentanyl.
Study NCT02427542 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CBT for Depersonalization/Derealization
Description: In addition to treatment as usual, six sessions of Cognitive Behavioural Therapy for Depersonalization/Derealisation covering psychoeducation, formulation, coping strategies.
Study NCT02427542 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual - in most cases case management/care coordination and may include medication
Study NCT02545699 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G-EYE™ Colonoscopy
Description: G-EYE™ Colonoscopy
Study NCT04468841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sample of saliva or fingernail clipping
Description: collected in clinic one time
Study NCT02545699 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Colonoscopy
Description: Standard Colonoscopy
Study NCT00008216 — intervention group
Intervention type: PROCEDURE
Intervention: Peripheral Blood Stem Cell Transplantation
Study NCT04197856 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care encouraging family-mediated disclosure of hereditary cancer risk
Description: At counseling, eligible at-risk relatives (who may benefit from disclosure of risk information) are listed on a specified protocol in collaboration between health care provider and the participant.
Study NCT04197856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care encouraging family-mediated disclosure of hereditary cancer risk
Description: At counseling, eligible at-risk relatives (who may benefit from disclosure of risk information) are listed on a specified protocol in collaboration between health care provider and the participant.
Study NCT04197856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Offer of health-care assisted disclosure by sending direct letters to at-risk relatives
Description: The participant is offered that the health care provider at the cancer genetic unit mail a direct letter with personalized family risk information to all at-risk relatives that participant approve contact with.
Study NCT02611193 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manipulative treatment
Description: Manipulative treatment as described by the GBMOIM (Grupo Barcelona de Medicina Ortopédica y Manual) will be perform with extension of the transverse carpal ligament maneuver and fascia release maneuver
Study NCT02611193 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Simulated manipulative treatment
Description: Simulated Manipulative Treatment
Study NCT00714064 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23vPPV, dTpa (Pneumovax, Boostrix)
Description: Group A will receive 23vPPV during 3rd trimester and dTpa at delivery
Study NCT00118937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Tablet Metformin 500 mg, Dosage: 1000 mg two times daily (2000 mg total daily dose).
Study NCT00118937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo.
Description: Tablet Placebo (corresponding to 500 mg metformin). Dosage: 1 tablet per day.
Study NCT00118937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo.
Description: Tablet Placebo (corresponding to 500 mg metformin). Dosage: 2 tablets two times daily.
Study NCT00714064 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23vPPV, dTpa (Pneumovax, Boostrix)
Description: Group B will receive 23vPPV at delivery and dTpa 7 months following delivery
Study NCT03363100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital health Partnership program
Description: The program pairs patients with their own certified diabetes educator coach who will guide the patient through a personalized program that leverages a proven educational curriculum combined with proven patient engagement methods.
Study NCT04468841 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pre-treatment test specimen
Description: From bone marrow, blood, lymph node, or alternate site to identify tumor-specific mutations. For retrospective patients initial tumor tissue (if available).
Study NCT02416947 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 0 g SCF
Description: 0 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
Study NCT02416947 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 10g SCF
Description: 10 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
Study NCT02416947 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 20g SCF
Description: 20 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
Study NCT04468841 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT, CT, or MRI testing
Description: PET/CT scans are required at baseline and at the patient's end-of-treatment visit. The other standard-of-care scan timepoints can be performed using PET/CT, dedicated CT, or MRI per the treating investigator's discretion.
Study NCT00098579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV
Study NCT00098579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00714064 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 23vPPV, dTpa (Pneumovax, Boostrix)
Description: Group C will receive dTpa at delivery and 23vPPV 7 months following delivery
Study NCT03468348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: patients scheduled for mastectomy and axillary evacuation for cancer breast will receive orally, 2 hours before the operation either, placebo capsule, duloxetine 30 mg,duloxetine 60 mg or duloxetine 90 mg capsule.
Study NCT03468348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Duloxetine
Description: patients scheduled for mastectomy and axillary evacuation for cancer breast will receive orally, 2 hours before the operation either, placebo capsule, duloxetine 30 mg,duloxetine 60 mg or duloxetine 90 mg capsule.
Study NCT02212275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethophan
Description: A single age and weight appropriate dose of over the counter Delsym Cough Syrup containing only DXM as an active ingredient.
Study NCT02212275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextromethophan
Description: A single age and weight appropriate dose of over the counter Delsym Cough Syrup containing only DXM as an active ingredient.
Study NCT01123044 — intervention group
Intervention type: BIOLOGICAL
Group type: NO_INTERVENTION
Intervention: conservative
Description: Undergo autologous transplantation of limbal epithelial cells cultured on amniotic membrane
Study NCT01123044 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: conservative
Description: Undergo autologous transplantation of limbal epithelial cells cultured on amniotic membrane
Study NCT02778893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conmana
Description: 125mg three times a day (TID) continuously
Study NCT02778893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 100mg one a day（QD）at night continuously,If can tolerance after 1 weeks to add to 200mg;
Study NCT05140109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 1: Cognitive-dissonance based program
Description: The first four sessions focus on body image and the last four sessions on eating behavior.
Study NCT05140109 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2: Mindfulness-based program
Description: The sessions focus on different contents as body image, eating behavior and emotion regulation.
Study NCT05140109 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm 3: Person-centered program
Description: The sessions are not structured. Participants can bring any subject they need to talk.
Study NCT04385784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance exercise program.
Description: Multimodal exercise program that combines strength, mobility, elasticity and postural control exercises. It develops once a week for a total of 24 weeks. Each session lasts one hour and is carried out in small groups of 8 to 10 people maximum.
Study NCT04385784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based exercise program.
Description: Exercises based on the OTAGO program that are carried out at home without supervision. Participants are explained to carry out the program three or four times a week in a safely way.
Study NCT04385784 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based exercise program.
Description: Exercises based on the OTAGO program that are carried out at home without supervision. Participants are explained to carry out the program three or four times a week in a safely way.
Study NCT01913366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CM-PST
Study NCT03084003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Almonds
Study NCT03084003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Graham crackers
Study NCT03890744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ModraDoc006/r
Description: Treatment with twice daily once weekly (BIDW) ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
Study NCT02440685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN002 Dose Escalation
Description: Multiple ascending doses of ASN002 assigned by cohort
Study NCT02440685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN002 RD
Description: Recommended dose of ASN002 from Part A
Study NCT01865643 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope
Description: The GlideScope is used to assist with difficult tracheal intubation.
Study NCT01865643 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: GlideScope
Description: The GlideScope is used to assist with difficult tracheal intubation.
Study NCT02750319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone
Study NCT01018680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 30 milligrams (mg) taken by mouth, once daily for 1 week, followed by 60 to 120 mg taken by mouth, once daily for 9 weeks.
Study NCT02750319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amiodarone
Study NCT01018680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taken by mouth, once daily for 10 weeks
Study NCT01749241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate ophthalmic ointment
Description: Thin ribbon ointment to assigned eye twice daily for 14 days
Study NCT01749241 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vehicle Ophthalmic Ointment
Description: Thin ribbon ointment to assigned eye twice daily for 14 days
Study NCT03053531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PockeTalker Hearing Assistive Device (HAD)
Description: Investigators will test impacts of the provision of the HAD on hearing and understanding, and preparation for discharge. Just prior to going home, consented subjects will answer a set of survey questions, using an electronic tablet to support impaired hearing.
Study NCT02545270 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Level of pneumoperitoneum 12-9-6 mmHg
Description: Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (12-9-6 mmHg) during desufflation.
Study NCT02545270 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Level of pneumoperitoneum 11-8-5 mmHg
Description: Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (11-8-5 mmHg) during desufflation.
Study NCT02545270 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Level of pneumoperitoneum 10-7-4 mmHg
Description: Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (10-7-4 mmHg) during desufflation.
Study NCT02852876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Description: Oral
Study NCT02750319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Study NCT02750319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01221350 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipoic acid
Description: Lipoic acid 600 mg dose (two 300 mg capsules) once daily in the morning. All patients continued their asthma treatments given by their primary care physician also they were allowed to use rescue medication on demand consisting in inhaled salbutamol. During basal and 8 weeks visits spirometry with bronchodilator challenge, sputum induction and quality of life questionnaires and asthma control test were performed.
Study NCT01221350 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (two capsules filled with 300 mg vehicle) once daily in the morning during 60 days. All patients continued their asthma treatments given by their primary care physician also they were allowed to use rescue medication on demand consisting in inhaled salbutamol. During basal and 8 weeks visits spirometry with bronchodilator challenge, sputum induction and quality of life questionnaires and asthma control test were performed
Study NCT04791618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health360x plus health coach
Description: Access to health360x which provides monitoring, in the moment color coded feedback and goal setting for self management skills
Study NCT04791618 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health360x only (High tech)
Description: All participants will have access to Helath360x with reminders generated for goal setting.
Study NCT04791618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health360x only (High tech)
Description: All participants will have access to Helath360x with reminders generated for goal setting.
Study NCT02156414 — intervention group
Intervention type: PROCEDURE
Intervention: Radical Prostatectomy
Description: Radical Prostatectomy
Study NCT02156414 — intervention group
Intervention type: PROCEDURE
Intervention: Extended Lymphadenectomy
Description: Extended Lymphadenectomy
Study NCT00904904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin ophthalmic solution
Description: Indomethacin 0.1% eye drops administered pre-cataract surgery and for 4 weeks post-cataract surgery
Study NCT01913366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SG-PST
Study NCT00904904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Ophthalmic Solution
Description: Ketorolac 0.5% eye drops administered pre-cataract surgery and 4 weeks post-cataract surgery
Study NCT02411019 — intervention group
Intervention type: BIOLOGICAL
Intervention: GX-188E
Description: In phase II study, 72 patients were assigned to two dose groups (1mg and 4mg) and were administered three times with GX-188E by electroporation during an entire period of study. After the final administration, the follow-up will be conducted to investigate safety and efficacy aspects.
Study NCT03117985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no drug
Description: Stopping antiretroviral therapy
Study NCT01860313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based interactive education
Description: An educational program for training teachers and educators to better recognize mental health problems in adolescents and children
Study NCT02852876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT00968565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium citrate
Description: Continuous infusion of 4% sodium citrate at 300 ml/hour into ECMO circuit
Study NCT06097208 — intervention group
Intervention type: BEHAVIORAL
Intervention: community-based health promotion and obesity prevention intervention
Description: The intervention involving measurements of children aged three- to four-years old in kindergartens, parents of the children had the opportunity of individual contact with a community health nurse, and education to kindergartens manager and employees e.g. pedagogues and kitchen staff. as well to parents of children in kindergartens.
Study NCT01674010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELND005
Study NCT01674010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Study NCT01674010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lamotrigine
Study NCT01674010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic acid
Study NCT01674010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Valproic acid
Study NCT01674010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01123044 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Medical Therapy
Description: Under usual care treatment
Study NCT00268450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Before surgery: given as a 70mg/m2 IV over 60 minutes every 21 days for 4 cycles
Study NCT04440137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bottle-feeding cessation program
Description: Specific brochure and proper oral hygiene education emphasizing on the benefit of stopping bottle-feeding given to subject
Study NCT04634617 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires